Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Fractyl Health, Inc. (GUTS)
NASDAQ:GUTS
GUTS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.37 - $10.50
Previous Close$1.96
Volume269.01K
Average Volume (3M)N/A
Market Cap
$73.59M
Enterprise Value$99.64M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta3.12
Next Earnings
Apr 07, 2025EPS Estimate
-0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.16
Shares Outstanding48,098,946
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.35
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.32K
Enterprise Value/Ebitda-1.23
Forecast
1Y Price Target
$8.00Price Target Upside447.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Fractyl Health, Inc. News
PremiumCompany Announcements
Fractyl Health Reprioritizes Focus on REMAIN-1 StudyPremiumCompany Announcements
Fractyl Health’s Promising Progress in Weight Management---
Bulls Say, Bears Say
Bulls Say
Obesity Treatment MarketFractyl Health's restructuring focuses on advancing its obesity treatment pipeline, which could offer significant upside potential.
Program Progress And Investor ConfidenceThe Revita and Rejuva programs are progressing as planned, with important data updates expected that could enhance investor confidence.
Bears Say
Diabetes Program ChallengesThe pause in diabetes research and workforce reduction reflects a strategic shift due to demand and financial considerations.
---
Ownership Overview
16.99% Insiders
3.99% Mutual Funds
37.82% Other Institutional Investors
35.82% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
GUTS FAQ
What was Fractyl Health, Inc.’s price range in the past 12 months?
Fractyl Health, Inc. lowest stock price was $1.37 and its highest was $10.50 in the past 12 months.
What is Fractyl Health, Inc.’s market cap?
Fractyl Health, Inc.’s market cap is $73.59M.
When is Fractyl Health, Inc.’s upcoming earnings report date?
Fractyl Health, Inc.’s upcoming earnings report date is Apr 07, 2025 which is in 44 days.
How were Fractyl Health, Inc.’s earnings last quarter?
Fractyl Health, Inc. released its earnings results on Nov 12, 2024. The company reported -$0.43 earnings per share for the quarter, beating the consensus estimate of -$0.5 by $0.07.
Is Fractyl Health, Inc. overvalued?
According to Wall Street analysts Fractyl Health, Inc.’s price is currently Undervalued.
Does Fractyl Health, Inc. pay dividends?
Fractyl Health, Inc. does not currently pay dividends.
What is Fractyl Health, Inc.’s EPS estimate?
Fractyl Health, Inc.’s EPS estimate is -0.44.
How many shares outstanding does Fractyl Health, Inc. have?
Fractyl Health, Inc. has 48,098,946 shares outstanding.
What happened to Fractyl Health, Inc.’s price movement after its last earnings report?
Fractyl Health, Inc. reported an EPS of -$0.43 in its last earnings report, beating expectations of -$0.5. Following the earnings report the stock price went down -2.469%.
Which hedge fund is a major shareholder of Fractyl Health, Inc.?
Currently, no hedge funds are holding shares in GUTS
---
Fractyl Health, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (447.95% Upside)
$8.00 (447.95% Upside)
Crowd Wisdom
Positive
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 4.8%
Last 30 Days ▲ 4.8%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.04%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
123.53%
Trailing 12-Months
GUTS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted significant progress in pivotal studies and FDA recognition, demonstrating strong potential for Fractyl's therapies in obesity and type 2 diabetes. However, financial challenges and the real-world limitations of GLP-1 drugs posed notable obstacles.Read More>---
GUTS Stock 12 Month Forecast
Average Price Target
$8.00
▲(447.95% Upside)
Technical Analysis
Exact Sciences
―
Pacific Biosciences
―
QuidelOrtho
―
Guardant Health
―
TransMedics Group
―
Best Analysts Covering GUTS
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-46.95%
reiterated a buy rating 23 days ago
Copying Michael Ulz's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -46.95% per trade.
---